CPT 15011-15018 (autologous skin cell suspension): commercial payer coverage 2026
Which US commercial payers cover an autologous skin cell suspension procedure billed as CPT 15011-15018, and which call it investigational. One row per payer, with the policy number, the stated date, a short summary, a verbatim quote where there is one, and a link to the payer’s own policy.
Last checked 2026-10-22. Sources are each payer's own public document. Where a payer has no readable public policy, this page says "could not verify" rather than guess a stance.
- No patient data
- No BAA
- No charge
- No pitch
Denied under CPT 15011-15018? The appeal starts in the payer's own text.
One letter per payer on this page that denies, written from that payer's current policy and the evidence it cites, re-issued when the policy changes. Or send one denial and read what comes back.
No patient data. Or send one denied claim by email: payer, code, denial reason.
What 15011-15018 are
CPT 15011-15018 are the Category I codes, new on 2025-01-01, for harvesting a small skin sample, preparing an autologous skin cell suspension and applying it to a wound and donor site, graded by body area. HCPCS C1832 (the device) and C8002 (automated preparation) sit next to them on a facility claim.
The device behind these codes is FDA-authorized (PMA) for acute thermal burns, full-thickness skin defects and stable vitiligo. Burn care is mostly inpatient, so a denial hits the hospital claim and the surgeon's 15011-15018 lines together.
Of the eight commercial payers read on 2026-10-22, one covers the burn indication with criteria (Anthem), six call the procedure investigational, experimental or unproven, and one (UnitedHealthcare) does not name the device or the codes in its skin substitute policy. That split is where the appeal starts: the denial has to be answered with the payer's own text.
Commercial payer coverage of CPT 15011-15018
8 payers with a verified stance, 0 that could not be verified. Each stance is the payer's own wording. Click a source to read the policy.
| Payer | Stance on CPT 15011-15018 | Date stated | What the policy says (short) | Source |
|---|---|---|---|---|
| Anthem (Elevance) Commercial (clinical UM guideline) | Medically necessary, with criteria (burns) | Last review 08/13/2026, published 08/27/2026 | Full-thickness or deep partial-thickness burns; other uses not medically necessary | anthem.com CG-SURG-127 |
| Aetna Commercial | Experimental / investigational / unproven | Last review 07/29/2026, next review 03/11/2027 | The device is on the E/I list; 15011-15018 are listed as related codes | aetna.com CPB 0244 |
| Cigna Commercial | Experimental / investigational / unproven for any indication | Effective 10/1/2026 (focused review), next review 3/15/2027 | Table row for the device, reason "Burn Care", codes 15011-15018 and C8002 | static.cigna.com, policy 0068 (PDF) |
| Premera Blue Cross Commercial (WA/AK) | Investigational | Last revised Oct. 1, 2026 (effective Aug. 1, 2026) | On the investigational list since 04/01/23; 15011-15018 coded to the device | premera.com 7.01.582 (PDF) |
| Blue Shield of California Commercial | Investigational | Effective October 1, 2026 (coding update; annual review 06/01/2026) | Item VII lists the device as investigational; 15011-15018 in the coding table | blueshieldca.com 7.01.113 (PDF) |
| Excellus BCBS Commercial (NY) | Experimental / investigational | 7.01.35 effective Aug 20, 2026; 7.01.11 effective Sep 17, 2026 | 7.01.35 codes 15011-15018 as E/I; 7.01.11 adds vitiligo (L80) as E/I | excellusbcbs.com 7.01.35 |
| Kaiser Permanente Washington Non-Medicare members | Unproven (non-Medicare members) | Last revised 06/09/2026 | 15011-15018, C1832 and C8002 on the unproven list; Medicare members follow CMS | wa-provider.kaiserpermanente.org (PDF) |
| UnitedHealthcare Commercial | Not named in the policy read | Effective August 1, 2026 | The policy names neither the device nor 15011-15018 | uhcprovider.com 2026T0592HH (PDF) |
Centene / Ambetter, Highmark, EmblemHealth, Florida Blue and Humana commercial were not verified on 2026-10-22 (Florida Blue MCG 02-10000-11 refused the connection), so their stance is not stated.
What each payer says
The quote is the payer's own, verbatim and under 30 words, linked to the source. The classification is the payer's, not ours.
Anthem (Elevance) Medically necessary, with criteria (burns)
CG-SURG-127, Products for Wound Healing and Soft Tissue Grafting: Medically Necessary Uses. Last review 08/13/2026, published 08/27/2026.
“considered medically necessary when used for the treatment of full-thickness or deep partial-thickness burns: ... ReCell Autologous Harvesting Device”
Anthem (Elevance), anthem.com CG-SURG-127
Lists 15011-15018, C1832 and C8002 under "Medically Necessary when criteria are met for burns". Other uses are not medically necessary. The only payer in this set that covers the burn indication.
Aetna Experimental / investigational / unproven
CPB 0244, Skin and Soft Tissue Substitutes. Last review 07/29/2026, next review 03/11/2027.
“considered experimental, investigational, or unproven because there is inadequate evidence in the peer-reviewed medical literature”
Aetna, aetna.com CPB 0244
The device is in the list of products the policy calls experimental, investigational or unproven. 15011-15018 are listed as related codes.
Cigna Experimental / investigational / unproven for any indication
Coverage Policy 0068, Tissue-Engineered Skin Substitutes. Effective 10/1/2026 (focused review), next review 3/15/2027.
“Considered Experimental/Investigational/Unproven when used to report RECELL”
The policy table lists the device with the reason "Burn Care" and the codes 15011-15018 and C8002. A separate code block carries the quote above.
Premera Blue Cross Investigational
7.01.582, Bioengineered Skin and Soft Tissue Substitutes. Last revised Oct. 1, 2026 (effective Aug. 1, 2026).
“The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.”
Premera Blue Cross, premera.com 7.01.582 (PDF)
The device was added to the investigational list on 04/01/23. The coding table marks 15011-15018 as the codes used to report it.
Blue Shield of California Investigational
7.01.113, Bioengineered Skin and Soft Tissue Substitutes. Effective October 1, 2026 (coding update; annual review 06/01/2026).
“considered investigational for indications reviewed herein”
Blue Shield of California, blueshieldca.com 7.01.113 (PDF)
Item VII of the policy lists the device among the products it calls investigational for the indications it reviews. 15011-15018 appear in the coding table.
Excellus BCBS Experimental / investigational
7.01.35, Bioengineered Tissue Products for Wound Treatment and Surgical Interventions; 7.01.11, Cosmetic and Reconstructive Procedures. 7.01.35 effective Aug 20, 2026; 7.01.11 effective Sep 17, 2026.
7.01.35 marks codes 15011-15018 "(E/I)". 7.01.11 lists autologous epidermal cell transplantation for skin repigmentation in vitiligo (15011-15018, C1832) as experimental and investigational for diagnosis L80.
Kaiser Permanente Washington Unproven (non-Medicare members)
New and Emerging Medical Technologies and Procedures (no policy number shown). Last revised 06/09/2026.
“considered to have unproven benefit because the current scientific evidence is not yet sufficient”
Kaiser Permanente Washington, wa-provider.kaiserpermanente.org (PDF)
15011-15018, C1832 and C8002 are in the list of technologies the criteria call unproven. Medicare members follow CMS.
UnitedHealthcare Not named in the policy read
2026T0592HH, Skin and Soft Tissue Substitutes. Effective August 1, 2026.
The full text of 2026T0592HH does not name the device or the codes 15011-15018 (0 matches on 2026-10-22). A UnitedHealthcare stance has to come from another UHC policy or from the denial letter itself.
What changed recently
- Cigna 0068 took effect 10/1/2026 after a focused review; the device stays experimental, investigational or unproven for any indication. Next review 3/15/2027.
- Premera 7.01.582 was last revised Oct. 1, 2026 (effective Aug. 1, 2026); Blue Shield of California 7.01.113 took effect October 1, 2026 as a coding update. Both keep the device investigational.
- Anthem CG-SURG-127 was reviewed 08/13/2026 and published 08/27/2026. It is the one policy in this set that calls the device medically necessary, for full-thickness or deep partial-thickness burns.
- Excellus 7.01.35 took effect Aug 20, 2026 and 7.01.11 on Sep 17, 2026. Aetna CPB 0244 was last reviewed 07/29/2026.
Medicare was not part of this check
Context only. Medicare was not part of the 2026-10-22 check. This page records commercial policies read on 2026-10-22. No NCD or LCD for CPT 15011-15018 was reviewed on that date, so no Medicare stance is stated here. Kaiser Permanente Washington notes that its Medicare members follow CMS.
Why these deny, and how the appeal works
No patient data. No BAA. No charge for the first one.
Most commercial 15011-15018 denials say one word: investigational. One payer in this set covers the burn indication with criteria, and the others say the evidence is not sufficient. The appeal has to answer that exact policy with its own words, the evidence it cites, the FDA authorization and the burn-specific facts of the case. Send us one denied 15011-15018 claim, payer and denial reason only, and you get back the appeal written from that payer’s policy within 24 hours. The first one is free.
Denied under CPT 15011-15018? The appeal starts in the payer's own text.
One letter per payer on this page that denies, written from that payer's current policy and the evidence it cites, re-issued when the policy changes. Or send one denial and read what comes back.
No patient data. Or send one denied claim by email: payer, code, denial reason.
Sources
Each payer's own public document, read on 2026-10-22. No logins, no click-through terms accepted. The stance wording is the payer's; we did not write it.
- Anthem (Elevance): CG-SURG-127, Products for Wound Healing and Soft Tissue Grafting: Medically Necessary Uses. anthem.com CG-SURG-127
- Aetna: CPB 0244, Skin and Soft Tissue Substitutes. aetna.com CPB 0244
- Cigna: Coverage Policy 0068, Tissue-Engineered Skin Substitutes. static.cigna.com, policy 0068 (PDF)
- Premera Blue Cross: 7.01.582, Bioengineered Skin and Soft Tissue Substitutes. premera.com 7.01.582 (PDF)
- Blue Shield of California: 7.01.113, Bioengineered Skin and Soft Tissue Substitutes. blueshieldca.com 7.01.113 (PDF)
- Excellus BCBS: 7.01.35, Bioengineered Tissue Products for Wound Treatment and Surgical Interventions; 7.01.11, Cosmetic and Reconstructive Procedures. excellusbcbs.com 7.01.35
- Kaiser Permanente Washington: New and Emerging Medical Technologies and Procedures (no policy number shown). wa-provider.kaiserpermanente.org (PDF)
- UnitedHealthcare: 2026T0592HH, Skin and Soft Tissue Substitutes. uhcprovider.com 2026T0592HH (PDF)